No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 21
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:22:00.730Z. Latest historical point 2026-09-30. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for CytoMed Therapeutics Limited (GDTC) stock was $1.01 as of Oct 5, 2026, 4:00 PM EDT, up 9.78% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -49.6% · 3-year avg -34.8%/yr
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies.
Biotechnology · Singapore, CE
LATEST PRICE
$1.01
52-WEEK RANGE
$0.68 - $3.68
BETA
0.05
% FROM 52W HIGH
-72.55%
MARKET CAP
$11.95M
DIVIDEND YIELD
Never paid
N/A
PE RATIO
trailing TTM
N/A
PE RATIO (FWD)
forward FY estimate
N/A
P/B RATIO
3.11
P/S RATIO
TTM
N/A
P/OCF RATIO
TTM
N/A
EV/EBITDA
TTM
N/A
DEBT / EQUITY
0.09
REVENUE TTM
$495.81K
GROSS MARGIN TTM
N/A
NET PROFIT MARGIN TTM
N/A
REVENUE GROWTH TTM
TTM vs prior TTM
N/A
REVENUE CAGR 3Y
N/A
REVENUE CAGR 5Y
N/A
TTM TOTAL RETURN
-49.59%
3Y TOTAL RETURN
annualized (CAGR)
-34.77%
5Y TOTAL RETURN
annualized (CAGR)
N/A
Next Earnings Date
Nov 13, 2026
38 days away
EPS Estimate
N/A
Revenue Est.
$127109.00
Last Quarter Results
EPS
N/A
vs Estimate
N/A
Revenue
$157673.00
vs Estimate
N/A
Consensus Rating
Based on 1 analyst
Average Price Target
$4.16
+311.9% upside
Low
$4.16
Current
$1.01
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | SGD 0.00 | SGD 0.00 | SGD 0.00 | 0 |
Quarterly
| Period | Low | Avg |
|---|
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1GDTC | $11.95M | $1.01 | +9.78% | -49.59% | N/A | N/A | N/A |
| 2IRIX | $11.94M | $0.69 | +7.28% | -42.35% | -38.13% | -26.14% | vs GDTC |
| 3CTSO | $12.46M | $3.96 | -2.10% | -79.67% | -52.26% | -28.72% | vs GDTC |
| 4ADIL | $11.42M | $4.35 | +5.58% | -56.33% | -71.86% | N/A | vs GDTC |
| 5BFRI | $11.41M | $0.89 | -12.23% | -16.67% | N/A | N/A | vs GDTC |
| 6DARE | $12.63M | $0.84 | +0.04% | -61.15% | -46.35% | -39.10% | vs GDTC |
High
$4.16
| High |
|---|
| # Analysts |
|---|
| Quarter ending Sep 2026 | SGD 162646.00 | SGD 162646.00 | SGD 162646.00 | 1 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
